Eric Langewisch, MD
Nephrology · Omaha, NENPI 1366576662
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,009 of the $2,702 with a category attached, or 74.3%. CSL Behring accounts for 91.2% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $2,465 and has fallen 95.5% since, to $112 in 2025.
Across 13 payments — averaging $207.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$2K
- Sanofi$125
- Biogen$112
Across 237 payments — averaging $839.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$199K
What the payments were for
- Travel & lodging$2,00974%
- Food & beverage$69326%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 11 | $2,465 |
| Sanofi | 1 | $125 |
| Biogen | 1 | $112 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THYMOGLOBULIN$125
How this compares
$2,702 in reported general payments places this provider in the 70th percentile of 60 nephrology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LokelmaSodium Zirconium Cyclosilicate | 11 | $17,129 |
| Tacrolimus | 32 | $6,015 |
| Valganciclovir Hcl | 11 | $4,233 |
| Cinacalcet Hcl | 17 | $3,973 |
| Mycophenolic AcidMycophenolate Sodium | 25 | $3,773 |
| Nifedipine ErNifedipine | 76 | $2,740 |
| Prednisone | 276 | $1,630 |
| Pravastatin Sodium | 13 | $1,235 |
| Carvedilol | 146 | $1,175 |
| Pantoprazole Sodium | 62 | $887 |
| Potassium Chloride | 21 | $698 |
| Losartan Potassium | 52 | $594 |
| Atorvastatin Calcium | 66 | $563 |
| Famotidine | 42 | $533 |
| Amlodipine Besylate | 51 | $530 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Omaha
- Richard LundOmaha$378K
- Jeffrey PasserOmaha$146K
- Roslyn MannonOmaha$64K
- Troy PlumbOmaha$17K
- Eric MagliuloOmaha$9K
- Prasanth RavipatiOmaha$7K
- Joseph BastOmaha$5K
- Stefan HemmingsOmaha$5K
- Sunil JagadeshOmaha$4K
- Judd BauerOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.